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Abstract
When a novel treatment has successfully passed phase I, different options to de-
sign subsequent phase II trials are available. One approach is a single-arm trial,
comparing the response rate in the intervention group against a fixed proportion.
Another alternative is to conduct a randomized phase II trial, comparing the new
treatment with placebo or the current standard. A significant problem arises in both
approaches when the investigated patient population is very heterogeneous regarding
prognostic factors. For the situation that a substantial dataset of historical controls
exists, we propose an approach to enhance the classic single-arm trial design by in-
cluding matched control patients. The outcome of the observed study population
can be adjusted based on the matched controls with a comparable distribution of
known confounders. We propose an adaptive two-stage design with the options of
early stopping for futility and recalculation of the sample size taking the matching
rate, number of matching partners, and observed treatment effect into account. The
performance of the proposed design in terms of type I error rate, power, and expected
sample size is investigated via simulation studies based on a hypothetical phase II
trial investigating a novel therapy for patients with acute myeloid leukemia.
Keywords: Adaptive designs, sample size recalculation, interim analysis, real world data,
acute myeloid leukemia
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1 Introduction
Phase II trials play a crucial role in drug development, serving to determine a first estimate
of the treatment effect after a successful phase I trial. Based on this estimate, it is decided
whether to initiate a subsequent phase III trial. Recently, many development programs,
particularly in oncology, failed (Gan et al., 2012), mainly due to lack of efficacy in either
phase II or phase III (Harrison, 2016). While the reasons for this high percentage are
heterogenous, Gan et al. (2010) pointed out that one problem for failed drug development
programs might be the inadequacy of the two commonly used standard approaches to
design a phase II trial, namely
1. using a single-arm design in which the observed response rate in the intervention
group is compared to a fixed proportion based on clinical judgment and historical
data, or
2. conducting a randomized controlled trial comparing the response rate under the novel
treatment against placebo or, if available, the current standard.
Single-arm trials ignore patient heterogeneity by design, which is, however, likely to arise
if there are strong prognostic factors associated with the treatment response. This un-
derlying patient heterogeneity representing an additional source of outcome variability is
ignored by the standard single-arm approach, which assumes that the enrolled patients are
identical to those in historical studies (Gan et al., 2010). On the other hand, randomized
controlled trials are likely to exhibit an imbalanced distribution of these factors across
treatment arms, thus leading to a highly variable treatment effect estimate (Gan et al.,
2010). Even though an analysis can be performed by including known confounders into the
statistical model, their imbalanced distribution across treatment arms may result in rather
unstable results (Redman and Crowley, 2007). This poses a problem regarding the subse-
quent go/no-go decision which has to be made based on a highly variable effect estimate.
Hence, neither of the two standard approaches is appropriate when the patient population
is quite heterogeneous, which is, however, often the case, e.g. in acute myeloid leukemia
(AML) (Schlenk et al., 2017) and cross entity approaches (Horak et al., 2017).
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There are currently some discussions in the scientific community how to make an effi-
cient and valid use of so-called ”real world data” (RWD) in the context of clinical trials
(Murdoch and Detsky, 2013; Corrigan-Curay et al., 2018). While the randomized con-
trolled trial is not challenged as the gold standard for the demonstration of treatment
efficacy in the context of phase III trials (Hudis, 2015), the implementation of RWD might
be of use to overcome the previously described disadvantages of the standard phase II de-
signs. While approaches allowing to incorporate such historical data into phase II trials
have been proposed in the Bayesian literature (Matano and Sambucini, 2016; Han et al.,
2017; Normington et al., 2020), this has, to our knowledge, not been done yet in a frequen-
tist design.
One potential source of RWD to enhance phase II trials is the registry data of historical
control patients. As an alternative data source, several clinical trial databases are currently
emerging, some of which have some kind of restricted access control mechanism, while
other databases have an open access policy (Broes et al., 2018). To name one controlled
access example, the Vivli database (Bierer et al., 2016) hosts the data of 4,700 clinical
trials from academia and industry (Vivli, 2020), with the option to analyse and share
individual participant-level data. One open-access example is the platform Project Data
Sphere (PDS) (Bertagnolli et al., 2017), which recently entered a partnership with Merck
KGaA (Merck KGaA, 2018), thereby enabling PDS to include high quality open access
data from rare tumor trials, experimental arm data and RWD.
If a substantial dataset of historical controls exists, we propose to use these data to
enhance a classic single-arm trial. This can be done by matching a number of suitable
control patients to each intervention patient. The selection of matched historical control
patients can practically be achieved by means of propensity score matching. The proposed
adaptive two-stage design allows to deal with uncertainties in the planning stage. Moreover,
the design enables to stop the trial for futility in case the interim treatment effect estimate
does not seem promising and to recalculate the sample size to be enrolled in the second
stage of the trial.
Our manuscript has the following structure. In Section 2, we outline some general
considerations, describe the underlying statistical framework and depict the characteristics
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of our design in terms of matching procedure, interim analysis, sample size recalculation
procedure, and treatment effect estimation. In Section 3, we investigate the performance
of the interim futility rule by means of an approximate formula for the probability to
continue the trial after the interim analysis. A simulation study motivated by a clinical trial
application is conducted in Section 4, where we investigate the performance characteristics
of standard phase II designs and the proposed design in terms of type I error, power,
and expected sample size, and also assess the performance of the matching procedure.
In Section 5, we conduct another simulation study to investigate the performance of the
proposed point and interval estimators. We conclude with a discussion in Section 6.
2 General considerations and design characteristics
In the proposed trial design, we assume that the primary outcome (Y i)i=1,... is a binary
variable, e.g. treatment response, with a value of ”1” representing a favorable, and a
value of ”0” representing an unfavorable outcome. Furthermore, there exists a set of
Nbin binary confounders {XBj : j = 1, 2, ..., Nbin} following a Bernoulli distribution with
(X iBj )i=1,... ∼i.i.d. Ber(pj) for all j = 1, 2, ..., Nbin and a set of Ncont known continuous
confounders {XCk : k = 1, 2, ..., Ncont}. Let furthermore (X iT )i=1,... denote the variable
assigning the treatment status, with X iT = 1 denoting that patient i was treated with the
novel treatment T and X iT = 0 denoting that the patient was treated with the control
treatment C. It is assumed that the primary outcome is distributed according to a logistic
regression model with
Logit(Y |XT , (XBj )j=1,...,Nbin, (XCj )j=1,...,Ncont) = β0 + θXT +
Nbin∑
j=1
βBjXBj +
Ncont∑
k=1
βCkXCk+ε,
where β0 is a scaling parameter, θ is the log odds ratio for the treatment effect, βBj , j =
1, ..., Nbin and βCk , k = 1, ..., Ncont are the log odds ratios for the respective confounders,
and ε = (εi)i=1,... denote the residuals for the log odds ratio of each particular patient.
It should be noted that we assume one homogenous treatment effect θ across all patient
strata.
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2.1 Trial design
The goal of our proposed trial design is to assess the treatment effect of the novel interven-
tion in terms of the log odds ratio θ for the primary outcome, while adjusting for relevant
known confounders. It is assumed that there is a pool of nC historical control patients
available. In our design, for each enrolled intervention patient, a suitable number of M
control patients is about to be drawn from the pool of control patients via a matching ap-
proach, which is described in more detail in Subsection 2.2. Based on the enrolled patients
treated with the novel therapy T and the selected historical control patients, the log odds
ratio for the primary outcome θ is estimated. The aim of our trial can either be
(i) a significant result obtained from a standard hypothesis test assessing the null hy-
pothesis H0 : θ ≤ 0 against the alternative H1 : θ > 0 at a prespecified one-sided
significance level α, or
(ii) an observed value θˆ that lies above a pre-defined threshold of clinical relevance θcross
on the log odds ratio scale, hence ”crossing the threshold” (Eichler et al., 2016). For-
mally, this is equivalent to obtaining a significant effect for a hypothesis test at a one-
sided α of 0.5 assessing the test problem H0 : θ − θcross ≤ 0 versus H1 : θ − θcross > 0.
The assessment of the respective hypotheses is done via an adaptive two-stage design,
which is depicted by means of a flowchart in Figure 1. In the proposed design, an initial
number of nI intervention patients are recruited. After recruitment is completed, a number
ofM matched control patients is selected for each of the enrolled patients. M is determined
using an iterative procedure (see the subsequent Subsection 2.2 for details), together with
the matching rate for stage I, mrI, i.e. the proportion of enrolled patients for which M
suitably matching control patients could be found. After the primary outcome is available
for all intervention patients to be included in stage I, the interim analysis is conducted.
The first step of the interim analysis is the estimation of θ using a logistic regression model
including the matching variables as confounders. In this model, only those intervention
patients for whomM matching partners could be found are included. Then, if the estimated
log odds ratio θˆI is smaller than a predefined futility threshold θstop, the trial is stopped for
futility and H0 is accepted. Otherwise, the trial will continue to stage II. Due to the fact
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that the a priori unknown number of matching partners M has an influence on the power
of the trial, the sample size for the second trial stage nII is recalculated based on the stage
I data using a conditional power argument (see Subsection 2.3 for details on the sample
size recalculation procedure).
After stage II of the trial has been completed, a 1:M matching is conducted for the
stage II intervention patients together with the stage I intervention patients who were not
included into the stage I logistic regression model since they did not haveM matching part-
ners. Those intervention patients for whom M matching control patients can be found will
be included into the stage II logistic regression model together with their matching partners.
It should be noted that the controls matched to the stage I patients are not reassigned such
that the test statistics of the two stages remain independent in order to ensure type I error
rate control. For the final analysis, the data from the two stages need to be combined for
the final hypothesis test. In the literature on adaptive designs, there exist several popular
approaches to do so, one being the use of a combination test which combines stage-wise
p-values into an overall p-value, e.g. using Fisher’s combination test (Bauer and Ko¨hne,
1994) or the inverse normal combination test (Lehmacher and Wassmer, 1999), the lat-
ter of which is used for the proposed trial design. Alternative approaches are the use of
the conditional error principle (Proschan and Hunsberger, 1995; Mu¨ller and Scha¨fer, 2004)
sharing a strong relationship with the combination test methodology (Vandemeulebroecke,
2006).
For our design, we make use of the inverse normal method proposed by Lehmacher and Wassmer
(1999) and Cui et al. (1999) with a priori specified weights wI for the stage I and wII for
stage II, respectively, with w2I + w
2
II = 1. If θˆI is the log odds ratio estimate from stage I
with standard error seI, and θˆII is the log odds ratio estimate from stage II with standard
error seII, then the respective one-sided p-values are defined as
pI = 1− Φ
(
θˆI − θcross
seI
)
,
pII = 1− Φ
(
θˆII − θcross
seII
)
, and
ptotal = 1− Φ
(
wIΦ
−1(1− pI) + wIIΦ−1(1− pII)
)
,
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where Φ(·) denotes the cumulative distribution function of the standard normal distribution
and Φ−1(·) its inverse. Note that in case one conducts a standard hypothesis test and does
not use a threshold-crossing approach, θcross = 0. If the combined p-value ptotal ≤ α,
H0 will be rejected. Since the p-values pI and pII can be assumed as independent and
uniformly distributed under the null hypothesis H0 : θ − θcross = 0, the same holds true
for the combined p-value ptotal, thus ensuring strict and exact control of the type I error
rate regardless of the adaptation done at interim (Lehmacher and Wassmer, 1999). While
a test using the inverse normal combination method will yield the maximal power when
these weights reflect the actual sample sizes of the two stages, the loss in power due to
over- or underweighting is rather limited if extreme sample size adaptations are avoided
(Lehmacher and Wassmer, 1999). If, e.g. one uses equal weights wI = wII = 1/
√
2 and
the ratio of the stage-wise sample sizes fulfills the condition 1/4 < nII/nI < 4, the loss in
power is usually less than 3 percent points (Wassmer and Brannath, 2016, p.149). Since we
will later on specify upper and lower bounds for the stage II sample size nII that allow to
avoid extreme discrepancies between combination test weights and stage-wise sample sizes,
choosing equal weights wI = wII appears to be a sensible choice for our proposed design.
2.2 Matching procedure
Propensity score matching is a method which aims to minimize the effect of observed
confounders in estimating treatment effects under the usage of observational data. The
propensity score is defined as the conditional probability of the assignment to a specific
therapy T under consideration of observed covariates. Hence, the propensity score function
e(X) is a balancing function of the observed confounders X , such that the conditional
distribution of X given the balancing score is the same in both groups and is defined as
follows
e(X) = P (T = 1|X),
under the assumption of
P (t1, . . . , tn|X1, . . . , Xn) =
N∏
i=1
e(Xi)
ti · (1− e(Xi))1−ti .
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This propensity score function can be estimated from observed data using, for example, a
logistic regression model (Rosenbaum and Rubin, 1983).
Within the considered adaptive two-stage design, a matching procedure is conducted
twice. In stage I, the matching determines the number M of matched controls per patient;
furthermore, an extrapolation of the matching rate for recalculating the sample size for the
second stage is done. In stage II, the matching is performed to find the fixed number of
matching partners M (determined in stage I) for the new patients in stage II. Obviously,
a high number of matching partners M will result in a more powerful trial. Nevertheless,
the matching rate, which decreases with increasing M , should also be sufficiently high,
since unmatched intervention patients will not be included into the statistical model, thus
lowering the power of the trial. The aim of our interim analysis is thus to determine a
suitable number of matched controls M which also ensures an adequately high matching
rate.
The propensity score model is estimated by using baseline characteristics as covariates
in a logistic regression model with treatment status as outcome variable. Available research
on variable selection in propensity score estimation suggests to include variables that influ-
ence the outcome or both the treatment selection and the outcome (Austin et al., 2007).
The resulting pro-pensity scores are transformed to the logit scale (Rosenbaum and Rubin,
1985). In the described situation, the propensity score model is defined as follows:
eˆ(X) = Logit
(
P (T = 1|X = X))= β˜0 + Nbin∑
j=1
β˜BjXBj +
Ncont∑
k=1
β˜CkXCk .
The patients are matched according to the logit of the estimated propensity score to the
control patients by using a caliper width of 0.2 of the standard deviation of these estimates
(Austin et al., 2007).
The procedure in stage I starts by conducting a 1:1 propensity score matching and cal-
culating the respective matching rate. Then, a 1:2 propensity score matching is performed
and the respective matching rate is calculated. We increase the number of matching part-
ners M as long as the matching rate is equal or higher than the 1:1 matching rate minus a
predefined tolerance criterion τ . This parameter defines the maximally allowed deviation
from the 1:1 matching rate. If, e.g., τ = 0, the 1:2 matching rate should not be smaller
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than the 1:1 matching rate, otherwise M will be set to 1. Choosing τ = 0 represents an
approach which ensures that a maximum number of intervention patients is included into
the analysis. If, on the other hand, τ = 0.05 and the 1:1 matching rate was 0.95, the
iterative procedure will increase M as long as the determined 1:M matching rate does not
fall below 0.95− 0.05 = 0.9. The pseudocode for the procedure is shown in Table 1.
Table 1: Pseudocode for setup of the matching procedure
step 1:
M = 1
perform 1:1 propensity score matching
calculate matching rate mr1:1
set M = 2
step 2:
perform 1:M propensity score matching
calculate matching rate mr1:M
if (mr1:1 − τ ) ≤ mr1:M
increase M to M + 1 and perform step 2
else
stop
To ensure that M suitable matching partners per intervention patient can still be found in
the second step, the maximum number of control patients per intervention patient Mmax
is predefined and the upper limit is given by
Mmax =
⌊
number of patients in the observational data
maximal number of patients in trial
⌋
.
After determining the number of matching partnersM and the corresponding matching
rate, the sample size for stage II is recalculated under consideration of the calculated
matching rate, which is described in the following Subsection 2.3. The matched pairs
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in stage I remain unchanged in stage II. Therefore, only the control patients without a
matching partner are considered for the matching in stage II. In the analysis of the stage II
data, a 1:M propensity score matching is conducted to find M matching partners for the
patients enrolled after the interim analysis. Note that the propensity score function in stage
II is estimated based on the samples of stage I without a matching partner, the enrolled
stage II patients and the remaining controls. The new propensity score model possibly
assigns different propensity scores which allows to possibly find a matching partner for
unmatched patients of stage I. If this is the case, those patients will be included in the
analysis of stage II data together with their matched control patients. Stage I intervention
patients for whom M matching control patients could neither be found at the stage I nor
at the stage II analysis, as well as stage II intervention patients for whom M matching
control patients could not be found at the stage II analysis are not considered in the final
analysis.
2.3 Interim analysis and sample size recalculation
Our proposed trial design includes an interim analysis with the option to stop the trial
for futility or to continue to stage II of the trial. Several methods are available for a
futility stop within a two-stage design, amongst others stopping rules based on p-values, or
criteria involving the conditional power at the interim analysis (Snapinn et al., 2006). As
the parameter θ representing the log odds ratio for the treatment effect plays a key role in
our design, we base the futility decision on a stopping boundary θstop on the log odds ratio
scale. This futility stop is considered as non-binding, and hence, no alpha reallocation
is conducted. Since the incorporation of a futility stopping rule tends to increase the
probability for a type II error, the performance characteristics of the stopping rule need to
be assessed in advance. If the threshold for futility stopping θstop is chosen too large, i.e. a
very strict stopping rule is applied, this will tend to increase the probability for a trial to be
falsely stopped at the interim analysis under H1. A necessary condition for P [θˆ ≤ θstop|H1]
is that this probability should not be higher than the aspired type II probability β.
If the interim estimate θˆI successfully crosses the futility threshold θstop, the sample size
for stage II is recalculated. Several concepts exist for sample size recalculation in adaptive
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trials, the two most popular approaches being the use of the frequentist conditional power
argument (Proschan and Hunsberger, 1995; Lehmacher and Wassmer, 1999; Liu and Chi,
2001; Friede and Kieser, 2001), which we will also use for our trial design, or the alternative
Bayesian concept of predictive power which requires the specification of a prior distribution
of the treatment effect (Spiegelhalter et al., 1986; Dmitrienko and Wang, 2006; Lan et al.,
2009). The option for sample size recalculation has both the advantage to take interim
estimates of the treatment effect and parameters which have an influence on the power of
the trial like the number of matching partners M and the stage I matching rate mrI into
account. A crucial aspect is the choice of the treatment effect θrecalc to be used for the
sample size recalculation. In this manuscript, we will consider two options for θrecalc:
(i) use of the originally assumed log odds ratio θplan to calculate the stage II sample size,
(ii) use of the interim estimate θˆI to calculate the stage II sample size.
While the first option will most likely result in relatively stable sample sizes, the treat-
ment effect assumed in the planning stage might be based on only vague prior information.
Hence, the second option has some advantages from a practical point of view, since it allows
to incorporate updated knowledge on the treatment effect. Nevertheless, since stage I of
the proposed design only incorporates few intervention patients, the interim effect estimate
θˆI might be unstable and thus yield unnecessarily high or too small sample sizes for stage II.
The performance of these two rules will later on be investigated by means of a simulation
study. Since our trial design incorporates a futility stop, excess sample sizes are unlikely
to occur since solely trials with a sufficiently high interim effect estimate continue to stage
II.
Let us assume without loss of generality that θcross = 0. In order to calculate the required
stage II sample size, we first determine the required information III for the second trial stage
in order to ensure a rejection probability at the end of stage II of at least cp, the so-called
conditional power. If θ ≥ θrecalc, according to the formula by Wassmer and Brannath (2016,
p.176), the stage II information amounts to
III =
(Φ−1(cp) + Φ−1(1−A(pI)))2
θ2recalc
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with
A(pI) = 1− Φ
(
Φ−1(1− α)− wIΦ−1(1− pI)
wII
)
being the conditional error function for the inverse normal method (Wassmer and Brannath,
2016, p.153). It is reasonable to assume that the information III is proportional to II = 1/se
2
I
with respect to the effective sample sizes of the two stages, i.e. III/II ≈ nII/(nI·mrI). Hence,
we obtain the stage II sample size formula
n∗II = nI ·mrI · se2I ·
(
Φ−1(cp) + Φ
−1(1−α)−wIΦ
−1(1−pI)
wII
)2
((θrecalc − θcross)+)2 ,
where (x)+ denotes the so-called positive part of a x ∈ R. Note that the denominator of
the above fraction needs to be positive since conditional power is defined only for a θrecalc
within the parameter space of the alternative hypothesis H1, which may not always be the
case when the interim estimate is used for sample size recalculation.
Regarding the final stage II sample size n˜II, a minimum sample size n
min
II and a maximum
sample size nmaxII have to be defined. While n
max
II should generally be chosen to reflect avail-
able trial resources in terms of trial duration and costs, nminII should not be too small in order
to prevent convergence problems for the stage II logistic regression model. Furthermore, the
final stage II sample size nII needs to take patients into account for whomM matching part-
ners cannot be found. Hence, an estimate of the stage II matching rate, mˆrII, needs to be
included into the sample size calculation. The determination of mˆrII can of course be done
using the naive estimate mˆrII = mrI, i.e. the stage I matching rate. We alternatively pro-
pose to use the lower limit of the one-sided 99%Wald-type confidence interval as an estimate
for the stage II matching rate, i.e. mˆrII = mrI − Φ−1(0.99) ·
√
mrI · (1−mrI)/(mrI · nI).
Obviously, the second approach leads to a higher stage II sample size. However, it will
account for a potentially smaller stage II matching rate due to fewer patients remaining
available for matching in the analysis of the stage II data. In the simulation study presented
in Section 4, we will also assess whether the proposed estimation of the stage II matching
rate actually provides a more or less accurate estimate of the observed stage II matching
rate.
The formula for the actual sample size required to be enrolled in stage II, n˜II, is accord-
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ingly given by
n˜II = max
{
nminII ,min {nmaxII , n∗II/mˆrII}
}
.
2.4 Point and interval estimation for treatment effect
As is the case for all designs with interim adaptations, the sequential and adaptive nature of
the trial needs to be taken into account when point and interval estimation of the treatment
effect is performed. We will propose some point estimators and interval estimator, and later
on investigate the point estimators in terms of bias and root mean square error (RMSE),
and the interval estimate in terms of coverage probability.
2.4.1 Point estimation
Three different types of point estimates for the log odds ratio of the treatment effect are
considered:
(i) the maximum likelihood (ML) estimator
θˆML =

mrInI
mrInI+mrIIn˜II
θˆI +
n˜II
mrInI+mrIIn˜II
θˆII if the trial continues to stage II,
θˆI else.
(ii) a fixed weighted maximum likelihood (FWML) estimator (Liu et al., 2002)
θˆFWML =
 ωθˆI + (1− ω)θˆII if the trial continues to stage II,θˆI else,
with ω being a pre-specified positive number satisfying 0 < ω < 1. ω can be chosen
deliberately, e.g. as the squared stage I weight used for p-value combination, i.e.
ω = w2I .
(iii) an adaptively weighted maximum likelihood (AWML) estimator (Cheng and Shen,
2004)
θˆAWML =
 ω˜θˆI + (1− ω˜)θˆII if the trial continues to stage II,θˆI else,
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with
ω˜ =
wI/seI
wI/seI + wII/seII
being an adaptive and non-prefixed weight due to its dependence on the stage I and
stage II standard errors seI and seII.
One should note that using the maximum likelihood estimate will most likely result in
some kind of bias due to the dependence between the first-stage effect estimate and the
stage II sample size n˜II (Brannath et al., 2006). Hence, alternative point estimates which
aim to reduce the bias such as θˆAWML and θˆFWML seem to be more promising methods at
first hand. The performance of these estimators in terms of bias and root mean square
error will be investigated in Section 5.
2.4.2 Interval estimation
For interval estimation, we propose to use the repeated confidence interval for the inverse
normal method (Wassmer and Brannath, 2016). This one-sided (1-α)-confidence interval
has the lower bound
lˆθ,1−α =
 θ˜ −
Φ−1(1−α)
wI/seI+wII/seII
if the trial continues to stage II,
θˆI − Φ−1(1− α) · seI else,
where θ˜ coincides with the adaptively weighted maximum likelihood estimator θˆAWML. In
Section 5, the coverage probability of this interval estimator will be assessed within the
proposed design by means of a simulation study.
15
Figure 1: Flowchart of the considered adaptive two-stage design
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3 Evaluation of the futility rule
As outlined in the previous section, the proposed trial design incorporates the option to
stop the trial for futility. Obviously, the futility rule defined by the stopping threshold θstop
should have desirable performance characteristics in the sense that both
(a) pθ∈H0stop = P [θˆI < θstop|θ ≤ θcross], being the probability for a futility stop under H0, and
(b) pθ∈H1continue = P [θˆI ≥ θstop|θ > θcross], being the probability for a continuation of the trial
after the interim analysis under H1,
are sufficiently high. Both pθ∈H0stop and p
θ∈H1
continue will of course increase with an increasing
stage I sample size nI. While a high stage I sample size is not only beneficial in terms of
an increased probability for a correct interim decision but also regarding the sample size
recalculation procedure in case the interim estimate is used, nI should of course not be
chosen too high due to budget and time constraints. Also, a high number of matching
partners M will increase the probabilities pθ∈H0stop and p
θ∈H1
continue, since M is proportional to
the sample size in the control group. Regarding the choice of the interim decision threshold
θstop, the situation is more complicated since a relatively high and thus conservative θstop
will yield a high pθ∈H0stop but a low p
θ∈H1
continue, while the opposite is true for a relatively small and
thus liberal θstop. When judging the overall design performance in terms of type I and type
II error rate control, a small pθ∈H0stop should not affect the type I error rate, since the type I
error rate is still controlled by the testing procedure at the significance level α. Nonetheless,
a small pθ∈H0stop will of course result in a frequent waste of resources and a treatment of more
patients with an inactive drug. Not only will trials erroneously continue to stage II with
a high probability, but in addition many patients are expected to be enrolled in stage II
since the recalculated sample size n˜II is likely to be rather high due to the small treatment
effect observed at interim. On the other hand, a high pθ∈H1stop will affect the type II error rate
β of the trial. This is due to the fact that the probability of a type II error will at least be
as high as the probability of a false futility stop, i.e. β ≥ pθ∈H1stop .
Hence, when planning a trial with the proposed design, investigations about the per-
formance of the futility stopping rule should be undertaken. While this can of course be
done via simulation studies, we will present an analytical method to facilitate application
17
by giving approximate formulae for pH0stop and p
H1
stop.
We can assume that the interim log odds ratio estimate θˆI is approximately normally
distributed (Agresti, 1999) and with asymptotic standard error
s˜eI =
√
1
n˜I · piT +
1
n˜I · (1− piT ) +
1
n˜I ·M · piC +
1
n˜I ·M · (1− piC) ,
(1)
where piT and piC are the proportions of responders amongst the treatment and the control
group and M is a fixed number of matching partners. The sample size n˜I := mrI · nI is the
number of intervention patients for which M suitable controls could be found and can be
regarded as the ”effective sample size” for stage I. Hence,
pθstop ≈ 1− Φ
(
θ − θstop
s˜eI
)
=: pˆθstop and p
θ
continue ≈ Φ
(
θ − θstop
s˜eI
)
=: pˆθcontinue. (2)
Now, as an example for the performance evaluation of the futility threshold, let us
consider the following scenarios:
• response rates piT = 0.3, piC = 0.3 under H0, i.e. θ = 0,
• response rates piT = 0.5, piC = 0.3 under H1, i.e. θ = log(2.33) ≈ 0.8473,
• stage I sample sizes n˜I = 10, . . . , 100 in steps of 10,
• stopping thresholds exp(θstop) = 1.1, 1.3, 1.5 on the odds ratio scale,
• number of matching partners M = 1, 2, 5, 10.
The results for pˆθ=0continue and pˆ
θ=log(2.33)
continue are presented in Figure 2. Regarding the number
of matching partners at the interim analysis, it can be observed that an increasing M will
always result in an improved performance of the interim decision rule. Nevertheless, while
the performance difference between M = 1, M = 2, and M = 5 is still substantial, the
difference between M = 5 and M = 10 seems almost negligible. Based on these results,
it appears that an extremely high number of matching partners such as M = 10 is not
substantially improving the performance of the interim decision. This can also be observed
in the approximation of the standard error s˜eI in equation 1, where an increasing M will
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Figure 2: Probabilities to continue to stage II under H0(θ = 0, dashed lines), and un-
der H1(θ = log(2.33), solid lines), in dependence of n˜I, denoting the number of stage I
intervention patients for which M suitable controls could be found.
θstop = log(1.1)
Sample size nI
P
ro
b
a
b
ili
ty
 t
o
 c
o
n
ti
n
u
e
 t
o
s
ta
g
e
 I
I
0 20 40 60 80 100
0
.0
0
.2
0
.4
0
.6
0
.8
1
.0
M=1
M=2
M=5
M=10
θstop = log(1.3)
Sample size nI
P
ro
b
a
b
ili
ty
 t
o
 c
o
n
ti
n
u
e
 t
o
s
ta
g
e
 I
I
0 20 40 60 80 100
0
.0
0
.2
0
.4
0
.6
0
.8
1
.0
θstop = log(1.5)
Sample size nI
P
ro
b
a
b
ili
ty
 t
o
 c
o
n
ti
n
u
e
 t
o
s
ta
g
e
 I
I
0 20 40 60 80 100
0
.0
0
.2
0
.4
0
.6
0
.8
1
.0
H0 H1
only lead to a convergence towards 0 for the last two terms under the root, while the first
two terms remain unchanged.
Obviously, an increasing sample size nI results in a better performance of the interim de-
cision rule since the statistical uncertainty about the treatment effect decreases. Regarding
the chosen interim decision threshold θstop, we can observe that θstop = log(1.1) performs
well under the alternative hypothesis H1 such that a probability for correctly continuing
to stage II is larger than 0.8 even for small nI and small M . Recall that in case a power
of 1− β = 0.8 is to be achieved for the trial, the probability to continue to stage II under
the alternative pθ∈H1continue should at least be 0.8. In case θstop = log(1.3), a sample size of at
least n˜I = 19 is required for p
θ∈H1
continue ≥ 0.8 if M = 1. For θstop = log(1.3), the required
stage I sample size increases to n˜I = 32 if M = 1. It should be noted that achieving a
value for pθ∈H1continue ≈ 0.8 is only a necessary requirement to yield a power at least as large as
0.8, since in this case every trial that continues to stage II must terminate with a rejection
of H0. This can of course only be achieved with a conditional power cp close to 1, which
will result in large sample sizes n˜II. Hence, achieving a p
θ∈H1
continue larger than 0.85 or even
0.9 seems to be more desirable from a practical point of view. Regarding the performance
of the decision rules under θ = 0, the most restrictive rule θstop = log(1.5) shows the over-
all best performance, while choosing θstop = log(1.1) performs worst. It appears that for
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θstop = log(1.1), increasing the stage I sample size nI does not have a substantial influence
on pθ∈H0continue, which ranges between 0.5 and 0.4, while for the other two decision thresholds,
the beneficial effect of an increasing sample size is more pronounced.
The previously derived formulae can furthermore be used to determine the conditional
power cp applied for sample size recalculation. Since
P [rejectH0|H1] = pθ∈H1continue · cp,
cp = (1− β)/pˆθplancontinue seems a sensible choice for the conditional power used for sample
size recalculation. In case that p
θplan
continue < (1− β), a maximum value for conditional power
such as cp = 0.99 can be chosen to recalculate the sample size such that there is a high
probability that a trial that was not stopped for futility leads to a rejection of H0 at the
final analysis.
It should be noted that the above formulae are only approximate and do not take
the additional variance caused by confounders into account. We will hence compare the
calculated stopping probabilities with simulated stopping probabilities in the following
section.
4 Simulation study
Let us consider the situation that a novel salvage treatment for refractory AML patients
is to be investigated in a phase II trial. AML is a disease known to be very heteroge-
neous (Papaemmanuil et al., 2016). Thus, it can be deemed unlikely that even known
predictors of response for refractory AML patients such as age and high risk cytogenetics
(Froehling et al., 2006) are distributed in a balanced manner across treatment arms when a
small randomized phase II trial is conducted (Schlenk et al., 2017). Also, a classical single-
arm trial will likely be subject to biased treatment effect estimates in this situation. It is
assumed that a large dataset containing AML patients treated with the current standard
treatment patients exists. Hence, it would be sensible to conduct a single-arm study with
the proposed design in this situation, taking the historical control patients into account.
It is assumed that the response rate under standard salvage therapy amounts to piC = 0.3,
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while it is hypothesized that a novel salvage therapy T can increase the response rate to
piT = 0.5. Based on the historical control data, the prevalence of high risk cytogenetics
in both treatment and control patients is assumed to be 0.34, while age is normally dis-
tributed with a mean of 55 years and a standard deviation of 15 years. It is assumed
that the response Y in the historical cohort conditional on age and high risk cytogenetics
(yes/no) can be modeled using a logistic regression model with
Logit(Y |XAge, XCyto) =β0 + βAgeXAge + βCytoXCyto+ε.
Including the variable ”treatment” into this model under the assumption of a log odds ratio
of θ = log
(
piT (1−piC)
piC(1−piT )
)
and assuming no interaction between covariate and treatment results
in the logistic model
Logit(Y |XT , XAge, XCyto) =β0 + θXT + βAgeXAge + βCytoXCyto+ε.
Let us assume that fitting this model on the historical control cohort leads to estimated
values of βˆ0 = 2, βˆAge = −0.05, βˆCyto = −0.5. Since the distribution of response variables is
apparently influenced by these two factors, it would be sensible to use these variables for
matching historical controls to treatment patients in the proposed design. In the planning
stage of the trial, the treatment effect assumed under H1 is θplan = log(0.7/0.3) ≈ log(2.33).
This underlying model achieves in expectation the envisaged response rates under H0 and
H1. Let us furthermore assume identically independently normally distributed residuals
ε = (εi)i=1,... ∼i.i.d. N(0, σ2).
In the following simulation study, we consider two situations prior to the start of the
trial: the existence of a smaller pool of nC = 500 historical control patients, and the
existence of a larger pool of nC = 1000 historical control patients. In the planning stage of
the trial, the stage I sample size of the trial nI and the futility stopping threshold θstop need
to be chosen. The methods proposed in Section 3 can be used to find suitable parameters
which achieve satisfactory probabilities for a correct interim decision under H0 and H1. In
the following, we will investigate the case of first-stage sample sizes of nI = 20, 25, and
30, and θstop = log(1.3) = 0.26 since the analytical formulae for a correct interim decision
which we derived in the previous section indicated a good performance of this threshold
under both H0 and H1. Prior to the initiation of a trial with the proposed design, it should
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additionally be assessed whether sample size recalculation should be based on the treatment
effect originally assumed in the planning stage θplan or the treatment effect estimated at
the interim analysis θˆI. This choice is of particular interest when the initially assumed
treatment effect may be misspecified. Furthermore, the tolerance criterion τ used in the
algorithm for the determination of the number of matching partners M should be chosen
adequately in order to yield both a sufficiently high number of matching partners and high
matching rates.
Also, we conducted simulation studies in which we investigated the performance of the
two standard approaches, namely
1. a single-arm trial in which no matched historical controls are incorporated, and which
assesses whether the response rate under the new treatment piT exceeds a historical
and fixed rate of 0.3, i.e. in which the hypothesis H0 : piT ≤ 0.3 is tested against
the alternative H1 : piT > 0.3. Assuming a treatment effect of piT = 0.5 under H1
would require n = 44 patients to be enrolled into this single-arm trial when using an
approximate version of the binomial test at a one-sided significance level of α = 0.025
to achieve a power of 1−β = 0.8 (calculations performed using ADDPLANTM v6.1).
2. a randomized two-arm trial in which no matched historical controls are incorporated,
but instead patients are randomly allocated to either receive treatment T or C, and
which assesses the null hypothesis H0 : piT ≤ piC versus the alternative hypothesis
H1 : piT > piC . Assuming piT = 0.5 and piC = 0.3 under H1 would require a total
sample size of n = 186 patients to be enrolled into this randomized controlled trial
when using the z-test for two independent proportions at a one-sided significance
level of α = 0.025. Since this can be deemed as an inconveniently large sample size
for a phase II trial, we instead consider the situation that a sample size of n = 100
patients (50 patients per group) are enrolled due to matters of feasibility (this sample
size also represents the chosen upper bound for the simulation study investigating
the proposed adaptive design). When using a z-test for two proportions at a (liberal)
one-sided significance level of α = 0.1 with this sample size at hand, the power should
amount to 1 − β = 0.78 when assuming that piT = 0.5, piC = 0.3 are the underlying
response rates. Besides of using the z-test, we also consider a scenario in which a
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logistic regression model adjusting for the prognostic confounders age and high risk
cytogenetics was used.
4.1 Simulation setup
The performance of the proposed design in terms of type I error rate control, power, and
sample size was assessed using a simulation study, which was conducted under the following
parameter specifications and assumptions:
• significance level α = 0.025
• aspired power 1− β = 0.8
• stopping threshold θstop = log(1.3)
• crossing threshold θcross = 0
• assumed treatment effect in the planning stage θplan = log(0.7/0.3) ≈ log(2.33) = 0.85
• under H0, a true treatment effect θ = 0
• under H1,
1. a true treatment effect θ = θplan = log(0.7/0.3) ≈ log(2.33) = 0.85
2. a slightly lower treatment effect θ = log(0.7/0.3 · 0.48/0.52) ≈ log(2.15) = 0.77
3. a slightly higher treatment effect θ = log(0.7/0.3 · 0.52/0.48) ≈ log(2.53) = 0.93
• to either recalculate the sample size based on θrecalc = θplan, or to recalculate it based
on the observed interim effect, i.e. θrecalc = θˆI
• conditional power cp = (1−β)/pˆθplancontinue used for sample size recalculation, with pˆθplancontinue
determined prior to the trial for all possible M using the formulae 1 and 2. The value
for M determined in the interim analysis then yields the cp chosen to recalculate the
sample size. In case pˆ
θplan
continue < 1− β, cp is set to 0.99.
• equal weights for the combination of stage I and II test statistics, i.e. w2I = w2II = 0.5
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• stage I sample sizes nI = 20, 25, and 30
• minimal and maximal stage II sample size of nminII = 10 and nmaxII = 100− nI
• historical control sample sizes nC = 500 or nC = 1000
• maximal number of matching partners Mmax = 5 in case nC = 500, and Mmax = 10
in case nC = 1000
• matching rate tolerance τ = 0, 0.05, and 0.1.
• age in years of control and intervention patients follows i.i.d. normal distributions
with expectation 55 and standard deviation 15.
• occurrence of high risk cytogenetics of control and intervention patients follows i.i.d.
Bernoulli distributions with event probability p = 0.34.
• response Y i of a given patient is distributed according to the previously described
logistic model with Logit(Y i|X iAge, X iCyto, X iT ) = 2 + θX iT − 0.05X iAge − 0.2X iCyto+εi
with residual standard deviations of σ = 0, 0.5 and 1.
• For the evaluation of the previously defined outcome distribution under standard
phase II designs, n = 44 patients are enrolled for the single-arm trial scenario, while
n = 100 patients (50 patients per group) are enrolled for the randomized controlled
trial scenario. The approximate test for a binomial proportion is used for the single-
arm trial at a one-sided significance level of α = 0.025, and either the z-test for two
independent proportions or a Wald test from a logistic regression model adjusting for
age and high risk cytogenetics is used for the randomized controlled trial, applying a
one-sided significance level of α = 0.1 for both tests.
100 000 replications were conducted for each scenario, yielding a standard error of
0.0005(0.0010) for the simulated type I error rate (assuming a true type I error rate of
0.025 (0.1)), and a maximal standard error of 0.0016 for the simulated power. Further-
more, in all scenarios we used the lower limit of the one-sided 99% Wald-type confidence
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interval as an estimate for the stage II matching rate when determining the stage II sample
size, as proposed in Subsection 2.3.
For the two cases nC = 500 and nC = 1000, we determined a hypothetical ”fixed design”
sample size nfixed denoting the number of patients required to achieve a power of at least
1 − β under the point alternative of the planned log odds ratio θplan = log(2.33) when
simply conducting a one-stage study enrolling nfixed patients (applying the same matching
algorithm and logistic regression model). This was done in order to compare the expected
sample size of our procedure with a reference value. For the investigation of the type I
error rate, we determined nfixed such that a power of at least 0.8 was achieved. For the
investigation of the power, we determined nfixed such that a power of at least the simulated
power of the respective scenario was reached in order to have a fair comparison. It should
be noted that this design is only hypothetical since matching rate and number of matching
partnersM of such a design are not known prior to the start of the trial, and thus no sample
size calculation can be performed. The sample size of such a design required to achieve a
power of at least 1 − β was also determined using 100 000 replications per scenario. The
same random seed as in the simulations of the adaptive two-stage design was used in order
to assess the identical collective of simulated patients. We conducted our simulations using
R (R Core Team, 2020) alongside the packages ”Matching” (Sekhon, 2011) and ”boot”
(Davison and Hinkley, 1997). All codes used for simulation are supplied as Supplementary
Material of this manuscript.
4.2 Simulation results
4.2.1 Type I error rate and power for standard designs
Table 2 shows the performance of the classic single-arm and randomized phase II design
in terms of the probability to reject H0. It can be observed that the standard procedures
did generally not achieve the aspired power, and that there was a slightly inflated type
I error rate for all designs. In case of the single-arm design, this might be due to the
fact that the average response rate for the treatment group under θ = 0 observed in our
simulations amounted to about 0.307 and thus was slightly larger than the value of 0.3 which
was specified as fixed proportion in the assessed null hypothesis. Vice versa, the average
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Table 2: Simulated probability to reject the null hypothesis prejectH0 , the average observed
response rates in both treatment and control group E[pˆiT ],E[pˆiC ] for a classic single-arm trial
with n = 44 patients and a randomized controlled trial (RCT) with n = 186 patients, using
θ = 0 under H0 and θ = θplan = log(0.7/0.3) under H1 for residual standard deviations of
σ = 0, 0.5, 1.
•
σ θ Model prejectH0 E[pˆiT ] E[pˆiC ]
σ = 0 θ = 0 single-arm trial (α = 0.025) 0.0281 0.3072 n.a.
RCT (z-test, α = 0.1) 0.1049 0.3076 0.3073
RCT (logistic regression, α = 0.1) 0.1035 0.3076 0.3073
σ = 0 θ = 0.85 single-arm trial (α = 0.025) 0.7053 0.4839 n.a.
RCT (z-test, α = 0.1) 0.6963 0.4839 0.3073
RCT (logistic regression, α = 0.1) 0.7410 0.4839 0.3073
σ = 0.5 θ = 0 single-arm trial (α = 0.025) 0.0362 0.3144 n.a.
RCT (z-test, α = 0.1) 0.1045 0.3143 0.3143
RCT (logistic regression, α = 0.1) 0.1036 0.3143 0.3143
σ = 0.5 θ = 0.85 single-arm trial (α = 0.025) 0.7115 0.4850 n.a.
RCT (z-test, α = 0.1) 0.6678 0.4843 0.3143
RCT (logistic regression, α = 0.1) 0.7154 0.4843 0.3143
σ = 1 θ = 0 single-arm trial (α = 0.025) 0.0595 0.3312 n.a.
RCT (z-test, α = 0.1) 0.1022 0.3310 0.3312
RCT (logistic regression, α = 0.1) 0.1029 0.3310 0.3312
σ = 1 θ = 0.85 single-arm trial (α = 0.025) 0.7188 0.4868 n.a.
RCT (z-test, α = 0.1) 0.6064 0.4859 0.3312
RCT (logistic regression, α = 0.1) 0.6468 0.4859 0.3312
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observed response rate under θ = 0.85 amounted to 0.484, and was thus below the value
of piT = 0.5 assumed in the sample size calculation. Nevertheless, under a binomial test
with a true response rate of piT = 0.484, a single-arm trial using the approximate binomial
test with n = 44 patients should have actually achieved a power of 0.7405 (calculated with
ADDPLANTM v6.1), thus indicating that there was a power loss due to the confounder-
induced heterogeneity. An increasing residual standard deviation σ resulted in increasing
and inflated type I error rates for the single-arm trial, while the power remained more or
less constant. In case of the randomized controlled trial, it could be generally observed that
the inclusion of the covariates by means of a logistic regression model is a more powerful
approach than the use of an unadjusted z-test. We identified a minimal inflation of the
type I error rate for the randomized controlled trial in all assessed scenarios, which can
however be deemed negligible. Nevertheless, it should be noted that using a z-test at a
significance level of α = 0.1 with a true response rate of piT = 0.484 and piC = 0.307, a
randomized controlled trial with n = 100 patients should actually achieve a power of 0.7045
(calculated with ADDPLANTM v6.1), thus indicating a rather small loss in power of only
1 percent point for the z-test. For an increasing residual standard deviation σ, however,
the power of the randomized controlled trial decreased substantially.
4.2.2 Type I error rate, power, and sample size for the proposed two-stage
design
Table 3 shows the simulation results under the null hypothesis for the proposed two-stage
design in case of a residual standard deviation of σ = 0. It can be observed that the type
I error rate is controlled at the defined significance level of α = 0.025 for all considered
scenarios. Also, the observed probabilities for a futility stop are only marginally smaller
to those values being calculated based on the formula presented in Section 3, where we
inserted the observed average number of matching partners M and the average stage I
matching rate mrI per simulated scenario. This shows overall good asymptotic properties
of our procedure under H0. For the considered situations, the expected sample size lies
considerably below the hypothetical fixed design sample size nfixed required to achieve a
power of 0.8, which was nfixed=65 for nC = 500 and nfixed=58 for nC = 1000. It can
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Table 3: Simulated type I error rate (probability to reject the null hypothesis prejectH0),
simulated probability for futility stop pstop, calculated approximate probability for a futility
stop pˆstop, expected sample size E[nI+ n˜II], and hypothetical fixed design sample size nfixed
required to achieve a power of 0.8 for varying sample sizes nI and nC , for θ = 0.
θrecalc nC nI prejectH0 pstop pˆstop E[nI + n˜II] nfixed
θplan 500 20 0.0242 0.6807 0.6868 42.18 65
500 25 0.0240 0.7010 0.7068 43.93 65
500 30 0.0235 0.7189 0.7242 46.41 65
1000 20 0.0245 0.6931 0.6946 39.54 58
1000 25 0.0252 0.7111 0.7152 41.73 58
1000 30 0.0242 0.7288 0.7333 44.54 58
θˆI 500 20 0.0243 0.6807 0.6868 42.07 65
500 25 0.0240 0.7010 0.7068 44.69 65
500 30 0.0235 0.7189 0.7242 47.51 65
1000 20 0.0241 0.6931 0.6946 40.92 58
1000 25 0.0240 0.7111 0.7152 43.82 58
1000 30 0.0242 0.7288 0.7333 46.77 58
Note: A matching rate tolerance of τ = 0.05 and a residual standard deviation of σ = 0 were
used to simulate all scenarios in this table.
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be observed that the probability for a correct futility stop is slightly higher in case of a
larger pool of control patients, which was to be expected since more control patients are
then included into the analysis, resulting in lower standard errors for the interim effect
estimator. Similarly, the expected sample size was smaller in case a larger pool of control
patients was available. When using the interim estimate for sample size recalculation, the
expected sample sizes of the procedure were slightly larger. This might be due to the fact
that interim estimates for those trials which were not stopped for futility are still expected
to be smaller than the planned treatment effect under H0, which in turn yielded higher
stage II sample sizes. When we investigated the distribution of the sample size, most of its
mass was distributed on two data points, being the minimal sample size nI and the maximal
sample size 100. In case of a residual standard deviation of σ = 0.5 and σ = 1, respectively,
the type I error rate was maintained as well (results provided in the Appendix).
Table 4 shows the performance of our design under H1 when the treatment effect as-
sumed in the planning stage is actually true, i.e. for θplan = θ = log(2.33). It can be
observed that the design achieves the aspired power of about 0.8 for most scenarios. If
nC = 500 and nI = 20, the power of the design is below 0.75 when using the interim
estimate for sample size recalculation. This indicates that the small sample size yielded
a relatively unstable interim estimate causing more trials to stop early for futility, which
might in turn have caused the loss in power. For the other scenarios, the fact that the
aspired power of 0.8 was missed by a narrow margin might be due to the upper bound
of 100 patients. This maximal sample size was apparently reached in some cases where
the actually recalculated sample size should have been higher in order to yield the aspired
power of 0.8. Also, the simulated probabilities to stop for futility are slightly above the
calculated ones. This might have caused a further loss in power due to a possibly too
small conditional power cp. It can be observed that our procedure yielded expected sample
sizes which were comparable or even slightly smaller than the sample size required in a
fixed design. In general, the higher the number of control and intervention patients, the
higher was the probability to reject H0. In case the sample size was recalculated based
on the originally assumed treatment effect θplan and nI = 25 patients were enrolled, this
yielded a higher power with smaller expected sample sizes as compared to nI = 20. This
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Table 4: Simulated power (probability to reject the null hypothesis prejectH0), simulated
probability for futility stop pstop, calculated approximate probability for a futility stop
pˆstop, expected sample size E[nI + n˜II], and hypothetical fixed design sample size nfixed
required to achieve the observed power in the respective scenario for varying sample sizes
nI and nC , and for using either θplan or θˆI for sample size recalculation, for a treatment
effect of θ = θplan = log(2.33).
θrecalc nC nI prejectH0 pstop pˆstop E[nI + n˜II] nfixed
θplan 500 20 0.7736 0.1389 0.1219 61.32 60
500 25 0.7839 0.1129 0.0964 59.95 62
500 30 0.7909 0.0922 0.0771 60.31 63
1000 20 0.7840 0.1262 0.1099 55.40 56
1000 25 0.7931 0.1009 0.0851 54.68 57
1000 30 0.8038 0.0809 0.0666 55.77 59
θˆI 500 20 0.7415 0.1389 0.1219 57.53 56
500 25 0.7678 0.1129 0.0964 59.76 60
500 30 0.7861 0.0922 0.0771 62.04 62
1000 20 0.7649 0.1262 0.1099 55.57 53
1000 25 0.7904 0.1009 0.0851 57.57 57
1000 30 0.8136 0.0809 0.0666 59.98 60
Note: A matching rate tolerance of τ = 0.05 and a residual standard deviation of σ = 0 were
used to simulate all scenarios in this table.
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indicates a superiority of the former approach in comparison to the latter in this particular
scenario. Recalculating the sample size based on the originally assumed treatment effect
yielded a slightly higher power with smaller expected sample sizes as compared to using the
interim estimate, thus indicating the superiority of the former approach for the scenario
θ = θplan = log(2.33). When the interim estimate was used, the expected sample sizes were
comparable or slightly above the hypothetical fixed design sample sizes.
Table 5 shows the performance of the design when the treatment effect was misspecified
in the planning stage. When we consider the scenario where the actual treatment effect
was smaller than the initially assumed treatment effect (θ = log(2.15)), using the interim
estimate instead of the originally planned treatment effect for sample size recalculation does
not yield an advantage in terms of power for nC = 500. The approach using θˆI works slightly
better in case nC = 1000 and nI ≥ 25, but does not achieve a power close to 0.8. This
might be due to the fact that the conditional power used in the simulation was calculated
based on the originally assumed treatment effect θplan. In case the actual treatment effect
was larger than the originally assumed one (θ = log(2.53)), using the interim estimate for
sample size recalculation showed a better performance in terms of smaller expected sample
sizes and a power closer to 0.8, with the exception of the scenario where nC = 1000 and
nI ≥ 25.
Tables 6 and 7 show the performance of the design under H1 in case of additional
variation induced by a residual with standard deviation σ = 0.5 and σ = 1, respectively.
It can be observed in Table 6 that a moderate residual standard deviation of σ = 0.5
leads to a small loss in power, an issue which was also observed earlier for the randomized
controlled trial design displayed in Table 2, and to a higher probability for falsely stopping
the trial at interim. Nevertheless, the expected sample size is still smaller for the proposed
design when compared to a corresponding sample size nfixed in case one uses the originally
assumed effect size for sample size recalculation, indicating that the proposed approach
seems to perform well nonetheless. The method using the interim estimate shows a slightly
worse performance in comparison, thus reflecting the results that were obtained in the
scenarios of a residual standard deviation of σ = 0 (displayed in Table 4). In case of a
large residual standard deviation σ = 1, the power decreases substantially to values only
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Table 5: Simulated power (probability to reject the null hypothesis prejectH0), probability
for futility stop pstop treatment effect, and expected sample size E[nI + n˜II] for varying
sample sizes nI and nC , and for using either θplan or θˆI for sample size recalculation, for
treatment effects θ = log(2.15) and θ = log(2.53), which differ from the planned effect of
θplan = log(2.33).
θ = log(2.15) θ = log(2.53)
θrecalc nC nI prejectH0 pstop E[nI + n˜II] prejectH0 pstop E[nI + n˜II]
θplan 500 20 0.7003 0.1744 61.89 0.8327 0.1078 60.32
500 25 0.7082 0.1486 61.02 0.8432 0.0836 58.33
500 30 0.7163 0.1257 61.86 0.8505 0.0650 58.41
1000 20 0.7112 0.1616 56.31 0.8413 0.0970 54.06
1000 25 0.7194 0.1352 56.02 0.8493 0.0736 53.01
1000 30 0.7319 0.1127 57.48 0.8590 0.0566 53.88
θˆI 500 20 0.6701 0.1744 58.63 0.7999 0.1078 55.99
500 25 0.6954 0.1486 61.21 0.8250 0.0836 57.71
500 30 0.7141 0.1257 63.98 0.8430 0.0650 59.74
1000 20 0.6967 0.1616 56.99 0.8189 0.0970 53.73
1000 25 0.7217 0.1352 59.45 0.8429 0.0736 55.38
1000 30 0.7473 0.1127 62.22 0.8626 0.0566 57.40
Note: A matching rate tolerance of τ = 0.05 and a residual standard deviation of σ = 0 were
used to simulate all scenarios in this table.
Table 6: Simulated power (probability to reject the null hypothesis prejectH0), simulated
probability for futility stop pstop, calculated approximate probability for a futility stop
pˆstop, expected sample size E[nI + n˜II], and hypothetical fixed design sample size nfixed
required to achieve the observed power in the respective scenario for varying sample sizes
nI and nC , and for using either θplan or θˆI for sample size recalculation, for a treatment
effect of θ = θplan = log(2.33) and residual standard deviation of σ = 0.5.
θrecalc nC nI prejectH0 pstop pˆstop E[nI + n˜II] nfixed
θplan 500 20 0.7406 0.1561 0.1219 61.29 61
500 25 0.7501 0.1278 0.0964 60.28 62
500 30 0.7587 0.1070 0.0771 60.71 63
1000 20 0.7498 0.1432 0.1099 55.41 56
1000 25 0.7606 0.1164 0.0851 55.01 57
1000 30 0.7709 0.0952 0.0666 56.27 59
θˆI 500 20 0.7105 0.1561 0.1219 58.10 56
500 25 0.7370 0.1278 0.0964 60.64 60
500 30 0.7584 0.1070 0.0771 62.97 63
1000 20 0.7340 0.1432 0.1099 56.13 54
1000 25 0.7624 0.1164 0.0851 58.53 58
1000 30 0.7853 0.0952 0.0666 61.07 61
Note: A matching rate tolerance of τ = 0.05 and a residual standard deviation of σ = 0.5 were
used to simulate all scenarios in this table.
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Table 7: Simulated power (probability to reject the null hypothesis prejectH0), simulated
probability for futility stop pstop, calculated approximate probability for a futility stop
pˆstop, expected sample size E[nI + n˜II], and hypothetical fixed design sample size nfixed
required to achieve the observed power in the respective scenario for varying sample sizes
nI and nC , and for using either θplan or θˆI for sample size recalculation, for a treatment
effect of θ = θplan = log(2.33) and residual standard deviation of σ = 1.
θrecalc nC nI prejectH0 pstop pˆstop E[nI + n˜II] nfixed
θplan 500 20 0.6518 0.1974 0.1219 60.76 61
500 25 0.6599 0.1699 0.0964 60.33 63
500 30 0.6678 0.1489 0.0771 61.22 64
1000 20 0.6640 0.1870 0.1099 55.17 57
1000 25 0.6692 0.1591 0.0851 55.34 58
1000 30 0.6798 0.1370 0.0666 56.92 60
θˆI 500 20 0.6270 0.1974 0.1219 58.90 58
500 25 0.6522 0.1699 0.0964 61.86 62
500 30 0.6745 0.1489 0.0771 64.57 65
1000 20 0.6527 0.1870 0.1099 57.27 56
1000 25 0.6802 0.1591 0.0851 60.11 60
1000 30 0.7039 0.1370 0.0666 62.98 63
Note: A matching rate tolerance of τ = 0.05 and a residual standard deviation of σ = 1 were
used to simulate all scenarios in this table.
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ranging between 63% and 70%. Also, the probability for a false stop for futility increases
remarkably if σ = 1.
4.2.3 Matching procedure
We also investigated the performance of the matching procedure in terms of the distribution
of the number of matching partners M , the matching rates in stage I and stage II, mrI and
mrII, and the potential influence on power, probability for a futility stop, and expected
sample size. For this assessment, we varied our tolerance criterion τ from the matching
algorithm by applying values of τ = 0, 0.05, 0.1. We only considered the situation of the
point alternative θ = θplan = log(2.33) in this investigation. Also, we only investigated
scenarios in which the sample size was recalculated using the originally assumed treatment
effect θplan. The results are shown in Table 8.
It can be observed that the expected number of matching partners E[M ] decreases with
an increasing sample size nI, since more adequate control patients have to be drawn from
the historical dataset. The expected stage II matching rates were smaller than their stage
I counterparts. This is plausible since M is not re-determined in the analysis of the stage
II data, and suitable partners for the second-stage patients are drawn from a diminished
pool of control patients since matching partners from stage I are not reallocated.
With an increasing tolerance criterion τ , the expected number of matching partners
increased while the matching rates for stage I and stage II decreased. While it seems desir-
able to enroll a high number of matching partners per intervention patient, the matching
rate should also be sufficiently high. In order to assess which tolerance criterion should be
preferable, it is sensible to take a look at the power and expected sample sizes. Choosing
τ = 0 yielded a slightly decreased power as compared to τ = 0.05, while the expected
sample size was even higher. Hence, choosing τ = 0 appears to be too strict by allowing no
deviation from 1:1 matching rate, thus not optimally making use of the available historical
controls.
Our proposed estimator for the stage II matching rate mˆrII seems to perform well when
τ = 0.05 and τ = 0.1, approximately yielding the observed matching rates. However, it
slightly overestimates the observed stage II matching rate in case of the strict matching
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Table 8: Expected number of matching partners E[M ], expected matching rates in stage
I and stage II E[mrI] and E[mrII], and mean estimated stage II matching rate for sample
size recalculation, alongside power (probability to reject the null hypothesis prejectH0), prob-
ability for futility stop pstop, and expected sample size E[nI + n˜II] for a treatment effect of
θ = θplan = log(2.33).
τ nC nI E[M ] E[mrI] E[mrII] E[mˆrII] prejectH0 pstop E[nI + n˜II]
0 500 20 4.43 0.9977 0.9406 0.9728 0.7658 0.1428 62.72
500 25 4.28 0.9977 0.9467 0.9754 0.7740 0.1181 61.97
500 30 4.14 0.9977 0.9496 0.9774 0.7815 0.0982 62.66
1000 20 8.81 0.9989 0.9546 0.9817 0.7774 0.1294 56.24
1000 25 8.52 0.9989 0.9586 0.9835 0.7860 0.1043 55.94
1000 30 8.24 0.9989 0.9594 0.9848 0.7961 0.0845 57.28
0.05 500 20 4.93 0.9862 0.9244 0.9255 0.7736 0.1389 61.32
500 25 4.88 0.9864 0.9281 0.9325 0.7839 0.1129 59.95
500 30 4.83 0.9866 0.9277 0.9378 0.7909 0.0922 60.31
1000 20 9.85 0.9866 0.9399 0.9268 0.7840 0.1262 55.40
1000 25 9.76 0.9868 0.9413 0.9337 0.7931 0.1009 54.68
1000 30 9.65 0.9870 0.9386 0.9389 0.8038 0.0809 55.77
0.1 500 20 4.99 0.9839 0.9215 0.9184 0.7739 0.1388 61.20
500 25 4.98 0.9834 0.9237 0.9240 0.7846 0.1125 59.75
500 30 4.99 0.9820 0.9198 0.9255 0.7922 0.0915 59.98
1000 20 9.98 0.9842 0.9372 0.9193 0.7842 0.1262 55.38
1000 25 9.97 0.9837 0.9372 0.9248 0.7939 0.1006 54.62
1000 30 9.99 0.9823 0.9311 0.9263 0.8044 0.0803 55.68
Note: For sample size recalculation, the originally assumed treatment effect θplan = log(2.33)
and a residual standard deviation of σ = 0 were used to simulate all scenarios in this table.
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tolerance criterion τ = 0. This also might be a reason why the aspired power of 0.8 was
not reached in these scenarios.
It should be mentioned that in some very few simulation runs, the logistic regression
model could not be fitted due to perfect separation of responders and non-responders in
the stage II analysis. In these rare situations, the stage II data was ignored for hypothesis
testing and estimation of the treatment effect. This aberration generally occurred for less
than 0.01% of all simulation runs and can thus be deemed irrelevant regarding the observed
overall performance characteristics of our design. Increasing the minimal stage II sample
size nminII will of course reduce the probability for such occurrences. We hence propose not
to choose nminII smaller than 10 patients in order to prevent such situations when conducting
a trial according to our design.
5 Performance of point and interval estimators
In order to assess the performance of the three point estimators and the interval estimator
presented in Subsection 2.4, we conducted a second simulation study for treatment effects
varying the log odds ratio of θ = −0.1 to θ = 2 in steps of 0.1. The significance level
was set to α = 0.025 and the residual standard deviation was σ = 0. The stage I sample
size was set to nI = 25, minimal and maximal stage II sample sizes were n
min
II = 10 and
nmaxII = 75, number of control patients was set to nC = 1000, sample size recalculation was
based on the originally assumed true effect, and equal weights were used for the two stages.
In order to assess the performance of the estimators combining two trial stages, no futility
stop was incorporated into the design, i.e. θstop was set to −∞.
As before, 100 000 replications per scenario were simulated. Bias and root mean square
error (RMSE) were determined for the maximum likelihood (ML), fixed weighted maximum
likelihood (FWML), and adaptively weighted maximum likelihood (AWML) estimator,
while the coverage probability of the proposed confidence interval was evaluated. The
weight for the FWML estimator was chosen to be the prespecified weight for the test
statistics, i.e. ω = w2I = 0.5. The results for bias and RMSE are shown in Figure 3, while
the coverage probability is displayed in Figure 4.
As can be seen in Figure 3, the maximum likelihood estimator is strongly biased for an
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Figure 3: Simulated bias and Root Mean Square Error (RMSE) for maximum likelihood
(ML), fixed weighted maximum likelihood (FWML) and adaptively weighted maximum
likelihood (AWML) estimator of the log odds ratio. Bias and RMSE are displayed on the
log odds ratio scale.
0.0 0.5 1.0 1.5 2.0
0
.0
0
.2
0
.4
0
.6
0
.8
1
.0
1
.2
Log odds ratio
B
ia
s
1 2 3 4 5 6 7 8
Odds ratio
ML
FWML
AWML
0.0 0.5 1.0 1.5 2.0
0
.0
0
.5
1
.0
1
.5
2
.0
2
.5
Log odds ratio
R
M
S
E
1 2 3 4 5 6 7 8
Odds ratio
ML
FWML
AWML
38
Figure 4: Simulated coverage probability of the proposed 97.5% confidence interval.
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increasing treatment effect and is thus not recommended as an estimator for the proposed
design. The FWML estimator yields only a small bias for odds ratios less than 3, but is
subject to a strong upward bias for larger log odds ratios. The AWML estimator only has
a small upward bias with a maximal bias of 0.06 and remains very stable for all considered
log odds ratios. Concerning the RMSE, the AWML estimator shows the uniformly best
performance as compared to the two other estimators. The RMSE remains more or less
constant for the AWML estimator, while it increases drastically for the other two estimators
with increasing treatment effect.
Figure 4 shows that the coverage probability of the proposed confidence interval is close
to 0.975, and shows a slight upwards tendency with an increasing treatment effect. For log
odds ratios smaller than 0.9, the estimated coverage probability was slightly below 0.975,
but deviations were small and might also be caused by a sampling error. Overall, the
proposed confidence interval seems to perform well in terms of coverage probability.
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6 Discussion
In this article, we developed and evaluated an adaptive two-stage design which can be used
in the context of phase II trials with a large dataset of historical controls at hand. The
proposed design overcomes commonly known disadvantages of standard phase II designs in
the case that confounding variables are strongly associated with the primary outcome. Our
frequentist approach combines two well-estab-lished methodological tools, namely matching
of historical controls and adaptive sample size recalculation within a two-stage design,
and is novel in two ways. On the one hand, it allows to incorporate matched historical
controls within a two-stage single-arm trial. On the other hand, applying the design enables
to deal with the uncertainty about trial parameters by means of an interim sample size
reassessment.
In a simulation study, we first investigated the potential problems of standard phase II
designs in case of strong prognostic confounders associated with the outcome. We observed
an inflation in the type I error rate for the single-arm design together with a decreased power
. For the randomized controlled trial design, there was only a negligible inflation of the
type I error rate, together with a slightly decreased power. Subsequently, we demonstrated
that our design performs well in terms of maintaining the nominal significance level .
Furthermore, it achieves the aspired power for most considered situations and shows a
good performance in terms of expected sample size. Regarding the choice of the effect
estimate on which the sample size recalculation is based, using the originally assumed
effect yielded a better performance in case this effect was also the true one. Possibly,
the approach using the interim estimate overestimated the true treatment effect in some
scenarios yielding a too small sample size leading to an acceptance ofH0. In other scenarios,
the interim estimate underestimated the actual treatment effect yielding too large sample
sizes. Deviations of the true effect from the assumed one could not be handled sufficiently
by using the estimated effect for sample size recalculation. The reason for this issue might
be the relatively small number of intervention patients based on which our treatment effect
was estimated causing a relatively large standard error for the interim estimate. Hence,
it might be sensible to rely on the originally assumed treatment effect when recalculating
the sample size. Alternatively, one possible method to overcome this issue might be the
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use of a combination of interim effect estimate and originally assumed effect, e.g. by using
Bayesian Posterior Mean (Wassmer and Brannath, 2016, p.180).
In case of strong additional variation induced by a residual in the simulation study, the
proposed design did not achieve the aspired power values anymore. While the loss in power
was rather small in case of a moderate residual standard deviation of σ = 0.5, for a large
residual standard deviation of σ = 1, the design only achieved power values between 65%
and 70%. Unfortunately, the degree of unobserved variation cannot be directly estimated
using logistic regression models (unlike in the case of a linear regression model). However,
when the originally planned treatment effect is used for sample size recalculation, our design
still yields expected sample sizes which are smaller than the sample size of a comparable
fixed design achieving the same power. We also found that the problem of strong residual
variance substantially impacts the power of a randomized controlled trial, the loss in power
thus also representing a problem for standard designs.
Another crucial aspect of the proposed design is the choice of the futility stopping
threshold. We provided approximate formulae for the probability for a futility stop, thus
enabling researchers to choose a threshold which performs adequately under both H0 and
H1 when planning a trial with our proposed design. Alternatively, the decision to stop for
futility can of course also be done using p-values or conditional power arguments.
Regarding the choice of suitable control patients, we relied on an iterative procedure and
used propensity score matching. Our proposed approach performed well in our simulations.
Regarding the choice of the tolerance criterion for the matching procedure, τ = 0.05 seemed
a good choice in the investigated scenarios. It should be noted that we assumed an equal
confounder distribution in intervention and control patients, which might not always be the
case in clinical practice. Nevertheless, if this assumption should not be met, our proposed
design is expected to perform well nonetheless since differences in terms of confounder
distribution between intervention and control patients would merely result in a smaller
number of adequate matching partners for each intervention patient. Since our sample size
recalculation procedure takes the number of matching partners into account, this situation
is expected to solely require larger trial sample sizes but maintaining adequate performance
in terms of type I error rate and power.
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When choosing a point estimator for the proposed design, the AWML estimator ap-
peared to be the overall best choice in our simulations since it had the overall smallest bias
and RMSE when compared to the alternative ML and FWML estimators. The repeated
confidence interval for the inverse normal method seems to be a suitable interval estimator
since it maintained the nominal coverage probability and has the nice property that it is
centered around the well-performing AWML estimator on the log odds ratio scale.
It is a crucial aspect that the historical control data are of high quality, e.g. covariates
used for matching should be measured in a standardized way and no missing values should
occur for either outcome or covariates. Our approach furthermore makes the implicit
assumption that the patients enrolled into the trial are comparable to their counterparts in
the historical control cohort. If this cannot be generally assumed, then quality control of
the existing control cases should be conducted, e.g. by removing historical control patients
which are not comparable to current patients. This will of course result in a smaller pool
of control patients and thus increase the required number of intervention patients, but will
decrease the potential for bias.
A limitation of our proposed design is that it is not possible to assess its performance
analytically. Instead, we had to rely on simulations. In order to achieve a high precision
for our estimates of type I error rate and power, we simulated 100 000 studies, which
took about three to four hours per scenario. Of course, increasing the sample size of
control or intervention patients, or taking more confounders into account will increase
the computational effort. Parallel programming can be used to simulate several scenarios
simultaneously though, thus reducing computation time.
When assessing the treatment effect, we relied on logistic regression models adjusting for
the confounders. The proposed design does however not rely on parametric assumptions,
and one might also consider non-parametric tests only adjusting for the matching strata
instead of the confounders, e.g. by using the Cochran-Mantel-Haenszel test (Agresti, 2002,
p. 114f) for hypothesis testing and the associated common odds ratio as interim decision
criterion. This method can be straightforwardly implemented in our proposed design, and
is also included as an optional approach in our R simulation code.
Our proposed design represents a novel frequentist approach when standard designs are
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likely to not maintain the aspired significance level and power due to strong prognostic fac-
tors. We are aware of its methodological complexity and the plethora of tuning parameters
that need to be chosen adequately and with care. Therefore, we provided our simulation
code such that research teams can perform simulation studies in the planning stage of their
trial. This will hopefully help to facilitate the use of our design and pave its way into
clinical practice. Currently, we are implementing this design in an actual phase II study
in AML patients with similar design specifications as shown in Section 4. We are hoping
that the actual implementation of our methods will help to gain visibility for our method
and encourage other researchers to use our proposed design as well.
We acknowledge the fact that the degree of evidence of our design is not comparable
with that of a large randomized controlled trial, since our approach only enables to balance
known confounders across treatment arms. Unrecognized confounders might still be un-
equally distributed across the two treatment groups of our design and possibly cause a bias
and loss in power (Betensky et al., 2002). Moreover, the proposed design is not immune
to a selection bias which might occur when either sampling the historical controls or the
intervention patients, but this is also an issue in classical single-arm designs which are still
frequently used in phase II oncology trials. We hence encourage the use of our design in
the context of the identification of a response signal in phase II trials in order to better
inform subsequent randomized phase III trials. This might reduce the number of failed
studies and increase the number of successful phase III trials, thus saving resources from
the perspective of patients, pharmaceutical companies, and health authorities.
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Appendix: Additional results on type I error rate of
the proposed design for further residual standard de-
viations
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Table A.1: Simulated type I error rate (probability to reject the null hypothesis prejectH0),
simulated probability for futility stop pstop, calculated approximate probability for a futility
stop pˆstop, and expected sample size E[nI+ n˜II] for varying sample sizes nI and nC , for θ = 0
and residual standard deviation σ = 0.5.
θrecalc nC nI prejectH0 pstop pˆstop E[nI + n˜II]
θplan 500 20 0.0246 0.6839 0.6868 41.91
500 25 0.0239 0.7061 0.7068 43.48
500 30 0.0243 0.7221 0.7242 46.14
1000 20 0.0241 0.6930 0.6946 39.44
1000 25 0.0236 0.7134 0.7152 41.42
1000 30 0.0237 0.7303 0.7333 44.29
θˆI 500 20 0.0244 0.6839 0.6868 41.94
500 25 0.0246 0.7061 0.7068 44.35
500 30 0.0242 0.7221 0.7242 47.34
1000 20 0.0239 0.6930 0.6946 40.97
1000 25 0.0235 0.7134 0.7152 43.65
1000 30 0.0233 0.7303 0.7333 46.69
Note: A matching rate tolerance of τ = 0.05 and a residual standard deviation of σ = 0.5 were
used to simulate all scenarios in this table.
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Table A.2: Simulated type I error rate (probability to reject the null hypothesis prejectH0),
simulated probability for futility stop pstop, calculated approximate probability for a futility
stop pˆstop, and expected sample size E[nI+ n˜II] for varying sample sizes nI and nC , for θ = 0
and residual standard deviation σ = 1.
θrecalc nC nI prejectH0 pstop pˆstop E[nI + n˜II]
θplan 500 20 0.0242 0.6881 0.6868 41.30
500 25 0.0237 0.7082 0.7068 43.06
500 30 0.0235 0.7256 0.7242 45.61
1000 20 0.0236 0.6981 0.6946 38.65
1000 25 0.0237 0.7175 0.7152 40.76
1000 30 0.0231 0.7346 0.7333 43.64
θˆI 500 20 0.0238 0.6881 0.6868 41.62
500 25 0.0234 0.7082 0.7068 44.25
500 30 0.0233 0.7256 0.7242 47.10
1000 20 0.0237 0.6981 0.6946 40.60
1000 25 0.0234 0.7175 0.7152 43.37
1000 30 0.0231 0.7346 0.7333 46.40
Note: A matching rate tolerance of τ = 0.05 and a residual standard deviation of σ = 1 were
used to simulate all scenarios in this table.
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